-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target

Benzinga·12/23/2025 13:44:12
Listen to the news
Citizens analyst Silvan Tuerkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $86 price target.